Simultaneous active intracellular delivery of doxorubicin and C6-ceramide shifts the additive/antagonistic drug interaction of non-encapsulated combination

Journal of Controlled Release

Volumn 196, Issue , 2014, Pages 122-131

  Fonseca, Nuno A ^a,b   Gomes Da Silva, Lígia C ^a   Moura, Vera ^a,c   Simões, Sérgio ^a,b   Moreira, João Nuno ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c Parque Industrial de Taveiro   (Portugal)

Author keywords

C6 ceramide; Combinatorial ratiometric drug design; F3 targeted delivery; Nanoparticles; Nucleolin

Indexed keywords

CELL DEATH; CELLS; CERAMIDES; CHEMOTHERAPY; CYTOLOGY; LIPOSOMES; NANOPARTICLES; TENDONS; TUMORS;

BREAST CANCER CELLS; C6-CERAMIDE; DRUG DESIGN; INTRACELLULAR DELIVERY; LIPOSOMAL DOXORUBICIN; NECROTIC CELL DEATHS; NUCLEOLIN; TARGETED DELIVERY;

DRUG INTERACTIONS;

ANTINEOPLASTIC AGENT; C6 CERAMIDE; CERAMIDE; DOXORUBICIN; LIPOSOME; NUCLEOLIN; PEPTIDE F; PEPTIDE F3; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; MACROGOL DERIVATIVE; N-CAPROYLSPHINGOSINE;

ARTICLE; CANCER CELL LINE; CELL VIABILITY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG POTENTIATION; ENCAPSULATION; HUMAN; HUMAN CELL; IC50; PH MEASUREMENT; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; DRUG INTERACTION; DRUG RESISTANCE; MEDICINAL CHEMISTRY; PH; TUMOR CELL LINE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; CERAMIDES; CHEMISTRY, PHARMACEUTICAL; DOXORUBICIN; DRUG DELIVERY SYSTEMS; DRUG INTERACTIONS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; HYDROGEN-ION CONCENTRATION; LIPOSOMES; POLYETHYLENE GLYCOLS;

EID: 84908159466     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.09.024     Document Type: Article

References (53)

1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J. Clin. 61 2011 69 90
2. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J. Clin. 63 2013 11 30
3. T. Saeki, T. Tsuruo, W. Sato, and K. Nishikawsa Drug resistance in chemotherapy for breast cancer Cancer Chemother. Pharmacol. 56 Suppl. 1 2005 84 89
4. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
5. A. Dicko, L.D. Mayer, and P.G. Tardi Use of nanoscale delivery systems to maintain synergistic drug ratios in vivo Expert Opin. Drug Deliv. 7 2010 1329 1341
6. S. Ramaswamy Rational design of cancer-drug combinations N. Engl. J. Med. 357 2007 299 300
7. J. Baselga Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer Oncologist 16 Suppl. 1 2011 12 19
8. K.D. Courtney, R.B. Corcoran, and J.A. Engelman The PI3K pathway as drug target in human cancer J. Clin. Oncol. 28 2010 1075 1083
9. H.J. Kim, J.E. Oh, S.W. Kim, Y.J. Chun, and M.Y. Kim Ceramide induces p38 MAPK-dependent apoptosis and Bax translocation via inhibition of Akt in HL-60 cells Cancer Lett. 260 2008 88 95
10. S.W. Kim, H.J. Kim, Y.J. Chun, and M.Y. Kim Ceramide produces apoptosis through induction of p27(kip1) by protein phosphatase 2A-dependent Akt dephosphorylation in PC-3 prostate cancer cells J. Toxicol. Environ. Health A 73 2010 1465 1476
11. Y.Y. Liu, V. Gupta, G.A. Patwardhan, K. Bhinge, Y. Zhao, J. Bao, H. Mehendale, M.C. Cabot, Y.T. Li, and S.M. Jazwinski Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling Mol. Cancer 9 2010 145
12. Y. Uchida, M. Itoh, Y. Taguchi, S. Yamaoka, H. Umehara, S. Ichikawa, Y. Hirabayashi, W.M. Holleran, and T. Okazaki Ceramide reduction and transcriptional up-regulation of glucosylceramide synthase through doxorubicin-activated Sp1 in drug-resistant HL-60/ADR cells Cancer Res. 64 2004 6271 6279
13. V. Gouaze, Y.Y. Liu, C.S. Prickett, J.Y. Yu, A.E. Giuliano, and M.C. Cabot Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs Cancer Res. 65 2005 3861 3867
14. Y.Y. Liu, J.Y. Yu, D. Yin, G.A. Patwardhan, V. Gupta, Y. Hirabayashi, W.M. Holleran, A.E. Giuliano, S.M. Jazwinski, V. Gouaze-Andersson, D.P. Consoli, and M.C. Cabot A role for ceramide in driving cancer cell resistance to doxorubicin FASEB J. 22 2008 2541 2551
15. C. Ji, B. Yang, Y.L. Yang, S.H. He, D.S. Miao, L. He, and Z.G. Bi Exogenous cell-permeable C6 ceramide sensitizes multiple cancer cell lines to doxorubicin-induced apoptosis by promoting AMPK activation and mTORC1 inhibition Oncogene 29 2010 6557 6568
16. R.R. Bansode Coupling in vitro and in vivo paradigm reveals a dose dependent inhibition of angiogenesis followed by initiation of autophagy by C6-ceramide Int. J. Biol. Sci. 2011 629 644
17. G. Bocci, A. Fioravanti, P. Orlandi, T. Di Desidero, G. Natale, G. Fanelli, P. Viacava, A.G. Naccarato, G. Francia, and R. Danesi Metronomic ceramide analogs inhibit angiogenesis in pancreatic cancer through up-regulation of caveolin-1 and thrombospondin-1 and down-regulation of cyclin D1 Neoplasia 14 2012 833 845
18. L.D. Mayer, T.O. Harasym, P.G. Tardi, N.L. Harasym, C.R. Shew, S.A. Johnstone, E.C. Ramsay, M.B. Bally, and A.S. Janoff Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice Mol. Cancer Ther. 5 2006 1854 1863
19. P. Tardi, S. Johnstone, N. Harasym, S. Xie, T. Harasym, N. Zisman, P. Harvie, D. Bermudes, and L. Mayer In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy Leuk. Res. 33 2009 129 139
20. E.J. Feldman, J.E. Lancet, J.E. Kolitz, E.K. Ritchie, G.J. Roboz, A.F. List, S.L. Allen, E. Asatiani, L.D. Mayer, C. Swenson, and A.C. Louie First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia J. Clin. Oncol. 29 2011 979 985
21. W.S. Lim, P.G. Tardi, N. Dos Santos, X. Xie, M. Fan, B.D. Liboiron, X. Huang, T.O. Harasym, D. Bermudes, and L.D. Mayer Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts Leuk. Res. 34 2010 1214 1223
22. V. Moura, M. Lacerda, P. Figueiredo, M.L. Corvo, M.E. Cruz, R. Soares, M.C. de Lima, S. Simoes, and J.N. Moreira Targeted and intracellular triggered delivery of therapeutics to cancer cells and the tumor microenvironment: impact on the treatment of breast cancer Breast Cancer Res. Treat. 133 2012 61 73
23. A.G. Hovanessian, C. Soundaramourty, D.E. Khoury, I. Nondier, J. Svab, and B. Krust Surface expressed nucleolin is constantly induced in tumor cells to mediate calcium-dependent ligand internalization PLoS One 5 2010 e15787
24. H. Shi, Y. Huang, H. Zhou, X. Song, S. Yuan, Y. Fu, and Y. Luo Nucleolin is a receptor that mediates antiangiogenic and antitumor activity of endostatin Blood 110 2007 2899 2906
25. S. Christian, J. Pilch, M.E. Akerman, K. Porkka, P. Laakkonen, and E. Ruoslahti Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels J. Cell Biol. 163 2003 871 878
26. M. Srivastava, and H.B. Pollard Molecular dissection of nucleolin's role in growth and cell proliferation: new insights FASEB J. 13 1999 1911 1922
27. T.C. Chou The mass-action law based algorithm for cost-effective approach for cancer drug discovery and development Am. J. Cancer Res. 1 2011 925 954
28. T.C. Chou Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies Pharmacol. Rev. 58 2006 621 681
29. T.C. Chou, and P. Talalay Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv. Enzyme Regul. 22 1984 27 55
30. J.M. Rae, C.J. Creighton, J.M. Meck, B.R. Haddad, and M.D. Johnson MDA-MB-435 cells are derived from M14 melanoma cells - a loss for breast cancer, but a boon for melanoma research Breast Cancer Res. Treat. 104 2007 13 19
31. J.N. Moreira, T. Ishida, R. Gaspar, and T.M. Allen Use of the post-insertion technique to insert peptide ligands into pre-formed stealth liposomes with retention of binding activity and cytotoxicity Pharm. Res. 19 2002 265 269
32. G. Haran, R. Cohen, L.K. Bar, and Y. Barenholz Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases Biochim. Biophys. Acta 1151 1993 201 215
33. A. Santos, A.B. Sarmento-Ribeiro, M.C. de Lima, S. Simoes, and J.N. Moreira Simultaneous evaluation of viability and Bcl-2 in small-cell lung cancer Cytometry A 73A 2008 1165 1172
34. B.S. Cummings, L.P. Wills, and R.G. Schnellmann Measurement of cell death in Mammalian cells Curr. Protoc. Pharmacol. 56 2012 12.8.1 12.8.24
35. T.C. Stover, A. Sharma, G.P. Robertson, and M. Kester Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma Clin. Cancer Res. 11 2005 3465 3474
36. A. Koshkaryev, A. Piroyan, and V.P. Torchilin Increased apoptosis in cancer cells in vitro and in vivo by ceramides in transferrin-modified liposomes Cancer Biol. Ther. 13 2012 50 60
37. E. Khazanov, A. Priev, J.P. Shillemans, and Y. Barenholz Physicochemical and biological characterization of ceramide-containing liposomes: paving the way to ceramide therapeutic application Langmuir 24 2008 6965 6980
38. L.E. van Vlerken, Z. Duan, M.V. Seiden, and M.M. Amiji Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer Cancer Res. 67 2007 4843 4850
39. S.A. Morad, J.P. Madigan, J.C. Levin, N. Abdelmageed, R. Karimi, D.W. Rosenberg, M. Kester, S.S. Shanmugavelandy, and M.C. Cabot Tamoxifen magnifies therapeutic impact of ceramide in human colorectal cancer cells independent of p53 Biochem. Pharmacol. 85 2013 1057 1065
40. M.A. Tran, C.D. Smith, M. Kester, and G.P. Robertson Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development Clin. Cancer Res. 14 2008 3571 3581
41. L.C. Gomes-da-Silva, A.O. Santos, L.M. Bimbo, V. Moura, J.S. Ramalho, M.C. Lima, S. Simoes, and J.N. Moreira Towards a siRNA-containing nanoparticle targeted to breast cancer cells and the tumor microenvironment Int. J. Pharm. 434 2012 9 19
42. K. Porkka, P. Laakkonen, J.A. Hoffman, M. Bernasconi, and E. Ruoslahti A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo Proc. Natl. Acad. Sci. U. S. A. 99 2002 7444 7449
43. T. Ishida, Y. Okada, T. Kobayashi, and H. Kiwada Development of pH-sensitive liposomes that efficiently retain encapsulated doxorubicin (DXR) in blood Int. J. Pharm. 309 2006 94 100
44. X. Li, and M. Schick Theory of tunable pH-sensitive vesicles of anionic and cationic lipids or anionic and neutral lipids Biophys. J. 80 2001 1703 1711
45. I.M. Hafez, and P.R. Cullis Cholesteryl hemisuccinate exhibits pH sensitive polymorphic phase behavior Biochim. Biophys. Acta 1463 2000 107 114
46. D. Agudelo, P. Bourassa, J. Bruneau, G. Berube, E. Asselin, and H.A. Tajmir-Riahi Probing the binding sites of antibiotic drugs doxorubicin and N-(trifluoroacetyl) doxorubicin with human and bovine serum albumins PLoS One 7 2012 e43814
47. T. Hernandez-Caselles, J. Villalain, and J.C. Gomez-Fernandez Influence of liposome charge and composition on their interaction with human blood serum proteins Mol. Cell. Biochem. 120 1993 119 126
48. P.G. Tardi, N. Dos Santos, T.O. Harasym, S.A. Johnstone, N. Zisman, A.W. Tsang, D.G. Bermudes, and L.D. Mayer Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo Mol. Cancer Ther. 8 2009 2266 2275
49. Y.W. Eom, M.A. Kim, S.S. Park, M.J. Goo, H.J. Kwon, S. Sohn, W.H. Kim, G. Yoon, and K.S. Choi Two distinct modes of cell death induced by doxorubicin: apoptosis and cell death through mitotic catastrophe accompanied by senescence-like phenotype Oncogene 24 2005 4765 4777
50. S. Mansilla, W. Priebe, and J. Portugal Mitotic catastrophe results in cell death by caspase-dependent and caspase-independent mechanisms Cell Cycle 5 2006 53 60
51. L.J. Siskind, T.D. Mullen, K. Romero Rosales, C.J. Clarke, M.J. Hernandez-Corbacho, A.L. Edinger, and L.M. Obeid The BCL-2 protein BAK is required for long-chain ceramide generation during apoptosis J. Biol. Chem. 285 2010 11818 11826
52. L.J. Siskind, R.N. Kolesnick, and M. Colombini Ceramide forms channels in mitochondrial outer membranes at physiologically relevant concentrations Mitochondrion 6 2006 118 125
53. L.J. Siskind Mitochondrial ceramide and the induction of apoptosis J. Bioenerg. Biomembr. 37 2005 143 153